RT Journal Article SR Electronic T1 The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA4519 DO 10.1183/13993003.congress-2019.PA4519 VO 54 IS suppl 63 A1 Yulia Kondakova A1 Elena Kondratyeva A1 Sergey Zyryanov A1 Irina Bondareva A1 Victoria Sherman A1 Yuliya Melyanovskaya YR 2019 UL http://erj.ersjournals.com/content/54/suppl_63/PA4519.abstract AB Introduction: Amoxicillin preparations and ciprofloxacin are widely used to treat infections in children with cystic fibrosis (CF).Objective: to study of factors affecting the pharmacokinetics of these drugs to select an effective dosing regimen. Materials and methods: Аmoxicillin / clavulanate and ciprofloxacin were administered as a single per os dose in children with CF between 2 and 16 years of age. Blood samples were obtained every 1.5 hours post dose for 7.5 hours. The concentration of amoxicillin and ciprofloxacin in serum was analyzed by high performance liquid chromatography. PK data were available in 35 children. Pharmacokinetic (PK) parameters were assessed using the non-compartmental method.Results: The PK profile of amoxicillin and ciprofloxacin varied widely among children with cystic fibrosis. The smallest values of the median maximum plasma concentration Cmax (µg / ml), Cmax norm (µg / ml) / (mg / kg), area under the time-concentration curve AUC0-t, µg * h / ml and area under the time-concentration curve (AUC) after normalization of doses to body weight AUC0-t norm, (µg * h / ml) / (mg / kg) were obtained in the subgroup of children ages 2-3 years old. The highest values of the median Cmax (µg / ml), Cmax norm (µg / ml) / (mg / kg), AUC0-t, µg * h / ml and AUC0-t norm, (µg * h / ml) / (mg / kg) were obtained in the subgroup of adolescents 12-16 years old.Conclusion: The data obtained indicate a relatively higher apparent total body clearance of amoxicillin and ciprofloxacin in the age subgroup of 2-3 years. The results require further study to identify factors affecting the pharmacokinetics of amoxicillin and ciprofloxacin in children with CF.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4519.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).